International Journal of Laboratory Hematology最新文献

{"title":"Correction to “Improving Platelet Function Following Prophylactic Platelet Transfusion in Patients With Hematological Malignancies”","authors":"","doi":"10.1111/ijlh.14481","DOIUrl":"10.1111/ijlh.14481","url":null,"abstract":"<p>Y. F. Wu, C. L. Shen, W. H. Huang, et al., “Improving Platelet Function Following Prophylactic Platelet Transfusion in Patients With Hematological Malignancies,” <i>International Journal of Laboratory Hematology</i> 46, no. 4 (2024): 722–730, https://doi.org/10.1111/ijlh.14283.</p><p>In the published article, on page 1 of the “Funding Information,” the text “Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Grant/Award Number: TCRD108-73” was incorrect. This should be corrected to: “Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Grant/Award Number: TCRD108-73, and Buddhist Tzu Chi Medical Foundation, Grant/Award Number: TCMMP112-01-03.”</p><p>On page 8 of the “ACKNOWLEDGEMENTS,” the text “This study was supported by a grant (TCRD108-73) from the Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Hualien, Taiwan.” was incorrect. This should be corrected to: “This study was supported by grants TCRD108-73 from the Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Hualien, Taiwan, and TCMMP112-01-03 from the Buddhist Tzu Chi Medical Foundation, Hualien Tzu Chi Hospital, Hualien, Taiwan.”</p><p>The authors apologize for the error.</p>","PeriodicalId":14120,"journal":{"name":"International Journal of Laboratory Hematology","volume":"47 4","pages":""},"PeriodicalIF":2.2,"publicationDate":"2025-05-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/ijlh.14481","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144180350","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pitfalls in Argatroban Monitoring: Heparin Interference With Dilute Thrombin Time Assays","authors":"Agathe Herb,&nbsp;Jordan Wimmer,&nbsp;Laurent Mauvieux,&nbsp;Laurent Sattler","doi":"10.1111/ijlh.14505","DOIUrl":"10.1111/ijlh.14505","url":null,"abstract":"&lt;p&gt;Direct thrombin inhibitors (DTI), such as argatroban, dabigatran, or bivalirudin, prolong clotting times due to their ability to bind and inhibit thrombin. Among these, argatroban requires particularly careful monitoring as it is commonly used to treat Heparin Induced Thrombocytopenia (HIT). This condition presents a dual risk: thrombosis caused by HIT and bleeding due to anticoagulation. For instance, Beyer et al. established that there was a 38% bleeding risk for supratherapeutic concentrations of argatroban, while subtherapeutic levels carried a 5% risk of thrombosis [&lt;span&gt;1&lt;/span&gt;].&lt;/p&gt;&lt;p&gt;To monitor argatroban, several assays are available, including activated partial thromboplastin time (aPTT), ecarin chromogenic assay (ECA) and dilute thrombin time (dTT). Studies have established that aPTT is not ideal for monitoring argatroban because of a plateau effect and a risk of non-therapeutic variations (for instance, CRP may prolong aPTT [&lt;span&gt;2, 3&lt;/span&gt;]), whereas ECA and dTT are more reliable and specific [&lt;span&gt;1, 4-6&lt;/span&gt;].&lt;/p&gt;&lt;p&gt;ECA utilizes ecarin, which derives from a snake venom and converts prothrombin into meizothrombin rather than thrombin. Meizothrombin is inactivated by DTI but unaffected by heparin [&lt;span&gt;7&lt;/span&gt;], making it useful for monitoring HIT patients on argatroban therapy.&lt;/p&gt;&lt;p&gt;In contrast, dTT consists of a thrombin time performed on a prediluted plasma, as standard thrombin time is too sensitive to DTI. While predilution can also reduce heparin interference, no study has yet evaluated the effect of heparin on dTT when used for argatroban measurement.&lt;/p&gt;&lt;p&gt;This issue is relevant because argatroban is typically administered immediately after stopping heparin for HIT treatment. As a result, both argatroban and heparin may be present in the bloodstream for a short period during this transition. Therefore, this study aims to assess whether heparin can interfere with argatroban measurement using a dTT assay.&lt;/p&gt;&lt;p&gt;In this study, approved by the institution's ethics board (CE-2024-103), samples collected during December 2024 from inpatients at University Hospital of Strasbourg (France) were included. Inclusion criteria were as follows: patients over 18 years old anticoagulated with unfractioned heparin (UFH) or enoxaparin. Underaged patients, patients undergoing a switch from another anticoagulant to heparin, or samples with insufficient plasma volume were excluded. Patient blood was drawn in Vacuette PET citrated tubes (Greiner Bio One, Kremsmünster, Austria) or Vacutest PET citrated tubes (Kima, Padua, Italy) with 0.109 M of trisodium citrate. Samples were centrifuged at 2500 g for 10 min at 20°C.&lt;/p&gt;&lt;p&gt;Anti-Xa activity (AXA) was measured using STA Liquid anti-Xa on a STA-R Max analyzer (both Diagnostica Stago, Asnières-sur-Seine, France) and anti-IIa activity was measured using a dTT assay, Hemoclot Thrombin Inhibitor (Hyphen Biomed, Neuville-sur-Oise, France), calibrated with an argatroban standard (Hyphen Biomed) ","PeriodicalId":14120,"journal":{"name":"International Journal of Laboratory Hematology","volume":"47 5","pages":"989-991"},"PeriodicalIF":2.3,"publicationDate":"2025-05-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/ijlh.14505","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144153099","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Trisomy 8 in De Novo Acute Myeloid Leukemia Lacking MDS-Related Cytogenetics Does Not Significantly Influence Survival","authors":"Adelaide J. Kwon,&nbsp;Miguel D. Cantu,&nbsp;Yazan F. Madanat,&nbsp;Robert P. Hasserjian,&nbsp;Prasad Koduru,&nbsp;Sa Wang,&nbsp;Guilin Tang,&nbsp;Olga K. Weinberg","doi":"10.1111/ijlh.14504","DOIUrl":"10.1111/ijlh.14504","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Introduction</h3>\u0000 \u0000 <p>The 2022 WHO and ICC classifications identify MDS-related cytogenetic abnormalities and secondary gene mutations (SM) that in de novo disease are diagnostic of myelodysplasia-related AML, which confers a poorer prognosis. While most MDS-related abnormalities overlap between the two classifications, trisomy 8 (+8) is unique to the ICC and has not been previously included as an MDS-related abnormality. In light of this, we sought to determine the prognostic significance of +8 as an MDS-related abnormality in patients with de novo AML lacking other MDS-related cytogenetics.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We identified 337 patients with de novo AML lacking MDS-related cytogenetics other than +8 and analyzed clinicopathologic outcomes, overall survival (OS), and relapse-free survival (RFS). Two groups were identified: AML with SM (<i>n</i> = 195, 57.9%) and AML without SM (<i>n</i> = 142, 42.1%). Fifty-nine (17.5%) patients had +8; 39 (66.1%) of these had at least one SM, while 20 (33.9%) did not.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Among patients treated with induction or hypomethylating agents (<i>n</i> = 317), OS and RFS were significantly shorter in patients with SM than without (OS: <i>p</i> = 0.001, RFS: <i>p</i> = 0.0004) but not significantly different between patients with and without +8 (OS: <i>p</i> = 0.15, RFS: <i>p</i> = 0.35). Similarly, when cases were limited to those with SM (<i>n</i> = 179), no significant difference in OS or RFS was observed between patients with and without +8 (OS: <i>p</i> = 0.21, RFS: <i>p</i> = 0.30). There was no significant association between +8 and SM (<i>p</i> = 0.15).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>In our cohort, unlike MDS-related SM, trisomy 8 does not influence OS or RFS, despite its inclusion in the ICC as an MDS-related abnormality.</p>\u0000 </section>\u0000 </div>","PeriodicalId":14120,"journal":{"name":"International Journal of Laboratory Hematology","volume":"47 5","pages":"884-890"},"PeriodicalIF":2.3,"publicationDate":"2025-05-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144153100","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dynamic ctDNA Monitoring: A Primary Tool Predictive of Response in a Patient on CAR-T Cell Therapy","authors":"Bhargava Rahul,&nbsp;Nathany Shrinidhi,&nbsp;Sen Ishita,&nbsp;M. Kumar Nikhil,&nbsp;Yadav Chitresh,&nbsp;Swaminathan Anusha,&nbsp;Thakrani Darshan,&nbsp;Verma Kanika,&nbsp;Saini Manish,&nbsp;Dua Vikas","doi":"10.1111/ijlh.14503","DOIUrl":"10.1111/ijlh.14503","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Introduction</h3>\u0000 \u0000 <p>Dynamic monitoring of circulating tumor DNA (ctDNA) offers a non-invasive method to track treatment response in malignancies. While well-established in solid tumors, its role in lymphomas, especially in predicting response to CAR-T cell therapy, remains underexplored—more so in the Indian context. This case highlights ctDNA as a potential predictive biomarker in relapsed/refractory DLBCL undergoing CAR-T therapy.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Case Report</h3>\u0000 \u0000 <p>A 48-year-old male with transformed follicular lymphoma to DLBCL, refractory to R-CHOP and BR, was treated with anti-CD19 CAR-T cell therapy. Baseline ctDNA profiling from plasma revealed a TP53 p.E286K mutation at 1.3% VAF. Serial monitoring showed a decline to 0.4% at four weeks and complete clearance at eight weeks post-infusion, correlating with metabolic complete response on PET-CT. No co-occurring mutations were observed.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Discussion</h3>\u0000 \u0000 <p>This case illustrates how dynamic ctDNA profiling can reflect early molecular response, preceding radiological confirmation. Existing literature suggests that early ctDNA negativity post-CAR-T correlates with improved outcomes. This is the first reported Indian case employing a validated, homebrew NGS-based ctDNA assay to longitudinally track CAR-T response. Incorporating ctDNA-guided surveillance may refine response assessment and reduce unnecessary imaging, optimizing outcomes in resource-constrained settings.</p>\u0000 </section>\u0000 </div>","PeriodicalId":14120,"journal":{"name":"International Journal of Laboratory Hematology","volume":"47 4","pages":"773-776"},"PeriodicalIF":2.2,"publicationDate":"2025-05-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144145248","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"International Council for Standardization in Haematology (ICSH) Guidance on the Validation of Laboratory Developed Tests in Haemostasis","authors":"Chris Gardiner,&nbsp;Akbar Dorgalaleh,&nbsp;Marión Echenagucia,&nbsp;Robert C. Gosselin,&nbsp;Teruto Hashiguchi,&nbsp;Mingting Peng,&nbsp;Alan Neal,&nbsp;Steve Kitchen","doi":"10.1111/ijlh.14502","DOIUrl":"10.1111/ijlh.14502","url":null,"abstract":"<p>Laboratory developed tests (LDTs) are widely used in clinical hemostasis laboratories. An LDT may be defined as an in vitro diagnostic (IVD) test that is designed, manufactured, and used within a single laboratory. As with all other clinical laboratory tests, LDTs must be validated to ensure fitness for purpose. This may include the assessment of accuracy/comparability, precision, analytical sensitivity, and specificity, reportable range, reference intervals, linearity, and carryover. Not all validation elements will be applicable to all situations, and this will be dictated by the type of assay, the intended use, and the laboratory setting, for example a minor modification of an assay with regulatory approval will require fewer validation procedures than a wholly new test using reagents developed within the laboratory. Many LDTs in the hemostasis laboratory cannot be assessed in the usual fashion, so alternative approaches must be developed.</p>","PeriodicalId":14120,"journal":{"name":"International Journal of Laboratory Hematology","volume":"47 4","pages":"600-612"},"PeriodicalIF":2.2,"publicationDate":"2025-05-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/ijlh.14502","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144129861","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diagnostic Value of Botryoid Nuclei as a Biomarker of Severe Hyperthermia and Systemic Inflammation in Heatstroke and Neuroleptic Malignant Syndrome: A Challenge of Climate Change","authors":"Gonzalo Verdú,&nbsp;Marina Vallvé,&nbsp;Paula San-José,&nbsp;Angel Molina,&nbsp;Anna Merino","doi":"10.1111/ijlh.14500","DOIUrl":"10.1111/ijlh.14500","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Introduction</h3>\u0000 \u0000 <p>With the increasing frequency of heat waves due to climate change, heat-related illnesses are becoming more common. Heatstroke is a life-threatening condition characterized by hyperthermia and multiple organ failure. A rare morphological feature, botryoid nuclei, has been identified in the peripheral blood of patients with hyperthermia, but its significance is not well understood. This study investigates the diagnostic value of botryoid neutrophils as a potential marker of severe hyperthermia and systemic inflammation in heatstroke and neuroleptic malignant syndrome.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We performed a retrospective analysis of six patients with hyperthermia who were admitted to the <i>Hospital Clínic of Barcelona</i> and the <i>Hospital de la Santa Creu i Sant Pau</i> during the summers of 2023 and 2024. Peripheral blood smears were analyzed using CellaVision DM9600, MC-80, and DI60 analyzers. Blood cell counts were obtained using Advia 2120i and Sysmex XN analyzers. Biochemical parameters were measured using Atellica Solutions and Alinity analyzers.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Among the six cases, five were diagnosed with heatstroke and one with neuroleptic malignant syndrome. All patients exhibited botryoid nuclei in leucocytes (8% to 29%), more frequently observed in neutrophils. Hematologic findings included leucocytosis, neutrophilia with left shift, and thrombocytopenia. Biochemical analysis revealed significant organ dysfunction, including elevated liver enzymes, renal failure, and increased inflammatory markers, such as procalcitonin and lactic acid.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Botryoid-nuclei leucocytes may serve as a diagnostic marker for hyperthermia-related conditions, including heatstroke and neuroleptic malignant syndrome. This finding underscores the relevance of early recognition and intervention in patients presenting with hyperthermia and systemic inflammation.</p>\u0000 </section>\u0000 </div>","PeriodicalId":14120,"journal":{"name":"International Journal of Laboratory Hematology","volume":"47 5","pages":"877-883"},"PeriodicalIF":2.3,"publicationDate":"2025-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144113136","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ring Chromosomes 7 in Two Cases of Myelodysplastic Syndrome: Isolated Abnormality and Complex Karyotype Including idic(21)(p11.2) Duplication","authors":"Katsuya Yamamoto,&nbsp;Keiji Kurata,&nbsp;Kimikazu Yakushijin,&nbsp;Hironobu Minami","doi":"10.1111/ijlh.14499","DOIUrl":"10.1111/ijlh.14499","url":null,"abstract":"","PeriodicalId":14120,"journal":{"name":"International Journal of Laboratory Hematology","volume":"47 5","pages":"791-793"},"PeriodicalIF":2.3,"publicationDate":"2025-05-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144096586","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Response to Dr. Sorigue's Letter Regarding Our Article: “A New Diagnostic Approach for Myelodysplastic Neoplasms Using a Combination of Scores Based on Flow Cytometry and Automated Hematology Sysmex XN Analyzers”","authors":"Ludovic Firrera,&nbsp;Benjamin Podvin,&nbsp;Julien Herlem,&nbsp;Marion Magierowicz,&nbsp;Alexandre Willaume,&nbsp;Vincent Thibaud,&nbsp;Agnès Charpentier","doi":"10.1111/ijlh.14496","DOIUrl":"10.1111/ijlh.14496","url":null,"abstract":"","PeriodicalId":14120,"journal":{"name":"International Journal of Laboratory Hematology","volume":"47 4","pages":"777-778"},"PeriodicalIF":2.2,"publicationDate":"2025-05-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144096584","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Time-Dependent EDTA Effect on Leukocyte Differential Count and Morphology Compared to Blood Smear Made by Direct Finger Prick","authors":"Anna Irding,&nbsp;Filip Landgren,&nbsp;Elisabeth Aardal","doi":"10.1111/ijlh.14498","DOIUrl":"10.1111/ijlh.14498","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Introduction</h3>\u0000 \u0000 <p>The impact of ethylenediaminetetraacetic acid (EDTA) on leukocyte count and morphology has led to the current recommendation that smears made from EDTA blood should be prepared within 4 h of sampling. However, previous studies have only been performed on smears with normal cell counts, and smears made from K₂EDTA blood have not been studied in comparison with smears made from direct finger prick. The aim of this study was to investigate the time limit for performing a morphological assessment on smears from EDTA blood without compromising the results.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Blood samples from 37 patients with known or suspected abnormal leukocyte morphology were selected, with smears from direct finger prick used as controls. Smears were prepared from the original EDTA tube every 4 h up to 24 h after sampling. The smears were evaluated for differential count, morphological assessment, and smear quality scoring.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>No significant difference in cell count was observed on smears made up to 12 h after sampling for neutrophils (<i>p</i> = 0.430), lymphocytes (<i>p</i> = 0.080), monocytes (<i>p</i> = 0.948) eosinophils (<i>p</i> = 0.398), basophils (<i>p</i> = 0.460), and blast cells (<i>p</i> = 0.239) compared to smears made by finger prick. However, smears prepared later than 8 h postsampling showed a significant increase in morphological changes.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>A manual differential leukocyte count can be reliably performed on smears from EDTA blood within 12 h, whereas a comprehensive morphological assessment requires smears to be prepared within 8 h of sampling.</p>\u0000 </section>\u0000 </div>","PeriodicalId":14120,"journal":{"name":"International Journal of Laboratory Hematology","volume":"47 5","pages":"826-831"},"PeriodicalIF":2.3,"publicationDate":"2025-05-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/ijlh.14498","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144082884","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Concentration Estimation of Apixaban and Rivaroxaban in Plasma From Patients Through Heparin-Calibrated Anti-Xa Assay Generated Different Results by Using 3 Reagent/Calibrators/Instrument Systems","authors":"Marta Elba Martinuzzo,&nbsp;Claudio Sebastián Berger,&nbsp;Emanuel Sueldo,&nbsp;Claudio Martín Rosa,&nbsp;Marina Sol López,&nbsp;Verónica Privitera,&nbsp;Fernando Chuliber,&nbsp;Luis Horacio Barrera,&nbsp;Mirta Arias,&nbsp;José Ceresetto,&nbsp;Cristina Duboscq","doi":"10.1111/ijlh.14497","DOIUrl":"10.1111/ijlh.14497","url":null,"abstract":"&lt;div&gt;\u0000 \u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Background&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Direct oral anti-Xa inhibitors are widely used in thrombosis treatment or prophylaxis. Despite the high safety profile, in clinical practice, the measurement of drug concentration in plasma is sometimes needed.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Objective&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;The aim was to compare results of three branches of reagents/calibrators/coagulometers for Heparin Calibrated Anti Xa assays (HC-Anti Xa) in samples from patients taking apixaban (APIXA) or rivaroxaban (RIVA).&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Methods&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Population: 49 samples from patients receiving APIXA (32–703 ng/mL) and 40 receiving RIVA (&lt; 8–573 ng/mL) taken at peak or trough. RIVA and APIXA measurement: HemosIL Liquid Anti Xa (Werfen) in ACL TOP 300 and STA-Liquid Anti Xa in STA Compact Max (Stago) with specific calibrators. HC-Anti Xa activity (1) HemosIL Heparin (Werfen) in ACL TOP 300; (2) Innovance Heparin (Siemens) in Sysmex CS-2500 (Siemens Health Care); (3) STA-Liquid Anti Xa (Stago) in STA COMPACT MAX coagulometer.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Results&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;HC-Anti Xa values paired compared showed statistically significant differences between the three systems, with the highest values obtained with the Stago system. An &lt;i&gt;r&lt;/i&gt;\u0000 &lt;sup&gt;2&lt;/sup&gt; &gt; 0.94 was found for Werfen and Siemens with samples with any drug, but &lt;i&gt;r&lt;/i&gt;\u0000 &lt;sup&gt;2&lt;/sup&gt; of 0.800 for APIXA and 0.792 for RIVA was observed in the Stago System due to a tendency to plateau at high drug concentrations. Analyzing only samples with concentrations ≤ 200 ng/mL, an &lt;i&gt;r&lt;/i&gt;\u0000 &lt;sup&gt;2&lt;/sup&gt; &gt; 0.93 with the three systems in APIXA (&lt;i&gt;n&lt;/i&gt; = 30) samples and 0.913, 0.875, and 0.906 in RIVA (&lt;i&gt;n&lt;/i&gt; = 31) samples with Werfen, Stago, and Siemens systems, respectively. Important differences inter systems in HC-Anti Xa calculated from regression lines were observed at 30, 50, 75, and 200 ng/mL of both drugs. Drug concentration measured by the Anti Xa assay calibrated with specific calibrators in 45 samples with APIXA and 27 with RIVA in Werfen and Stago systems showed very good correlation (&lt;i&gt;r&lt;/i&gt;\u0000 &lt;sup&gt;2&lt;/sup&gt; = 0.991 and 0.976, respectively).&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Conclusion&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Estimation of APIXA or RIVA concentration through HC-Anti Xa is possible, but values obtained are different for each reagent/calibrator/instrument system. Knowledge of the HC-Anti Xa values corresponding to anticoagulant concentrations at clinical decision points in the system used by each laboratory is mandatory to be able to use them cor","PeriodicalId":14120,"journal":{"name":"International Journal of Laboratory Hematology","volume":"47 5","pages":"931-937"},"PeriodicalIF":2.3,"publicationDate":"2025-05-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144059131","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}